Immuneering (IMRX) Total Liabilities: 2020-2024
Historic Total Liabilities for Immuneering (IMRX) over the last 4 years, with Sep 2024 value amounting to $10.8 million.
- Immuneering's Total Liabilities rose 9.86% to $10.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $10.8 million, marking a year-over-year increase of 9.86%. This contributed to the annual value of $12.0 million for FY2023, which is 4.06% down from last year.
- According to the latest figures from Q3 2024, Immuneering's Total Liabilities is $10.8 million, which was up 0.51% from $10.8 million recorded in Q2 2024.
- Immuneering's Total Liabilities' 5-year high stood at $12.5 million during Q4 2022, with a 5-year trough of $2.8 million in Q4 2020.
- Its 3-year average for Total Liabilities is $10.3 million, with a median of $9.9 million in 2023.
- Its Total Liabilities has fluctuated over the past 5 years, first spiked by 282.94% in 2021, then fell by 16.40% in 2023.
- Over the past 5 years, Immuneering's Total Liabilities (Quarterly) stood at $2.8 million in 2020, then soared by 282.94% to $10.7 million in 2021, then increased by 16.71% to $12.5 million in 2022, then fell by 4.06% to $12.0 million in 2023, then grew by 9.86% to $10.8 million in 2024.
- Its Total Liabilities was $10.8 million in Q3 2024, compared to $10.8 million in Q2 2024 and $9.3 million in Q1 2024.